Barclays’s AEON Biopharma AEON Stock Holding History

Barclays’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$0	Sell	1 -58	-98%	-$18	﹤0.01%	5373
2026 Q2	$42	Buy	+59	New	+$49	﹤0.01%	5251
2025 Q4	–	Sell	-21	Closed	-$17	–	5204
2025 Q3	$17	Buy	+21	New	+$16	﹤0.01%	5368
2023 Q3	–	Sell	-3	Closed	-$1.37K	–	4581
2023 Q2	$1.37K	Hold	3	–	–	﹤0.01%	4342
2023 Q1	$1.97K	Sell	3 -283	-99%	-$205K	﹤0.01%	4892
2022 Q4	$207K	Hold	286	–	–	﹤0.01%	3822
2022 Q3	$203K	Buy	+286	New	+$203K	﹤0.01%	3195

Other funds holding AEON

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Formidable Asset Management Cincinnati, Ohio $680M AUM 8.59% 1-Year Est. Return

Beacon Wealthcare LLC Raleigh, North Carolina $315M AUM 8.23% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Wolff Wiese Magana Carslbad, California $218M AUM 37.48% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $14.8M AUM 14.32% 1-Year Est. Return

GHP Investment Advisors Denver, Colorado $2.68B AUM 19.3% 1-Year Est. Return

Barclays's AEON Position: Q3 2026 in Review

Barclays reduced its AEON Biopharma (AEON) stake by 98% in Q3 2026, selling an estimated $18 and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5373.

Barclays first reported a position in AEON in Q3 2022 and has held it in 7 quarters since. The position peaked at $207K in Q4 2022. 10 funds tracked by Wall St. Rank hold AEON as of Q3 2026.

Barclays held 1 share of AEON Biopharma worth $0 as of Q3 2026.
Barclays sold 58 AEON Biopharma shares in Q3 2026, an estimated $18.
AEON Biopharma made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5373 holding.
Barclays first reported a position in AEON Biopharma in Q3 2022 and has held it in 7 quarters since.
Barclays's AEON Biopharma position peaked at $207K in Q4 2022.
10 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.